Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.
Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity.
Treatment of Neuropathic Pain and Functional Limitations Associated With Multiple Sclerosis Using an MRI-Compatible Spinal Cord Stimulator: A Case Report With Two Year Follow-Up and Literature Review.
A bird's-eye view of T cells during natalizumab therapy.
The Afferent Visual Pathway: Designing a Structural-Functional Paradigm of Multiple Sclerosis.
Simvastatin regulates oligodendroglial process dynamics and survival.
Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis.
A Randomized Controlled Trial of Cognitive Behavioral Therapy (CBT) for Adjusting to Multiple Sclerosis (the saMS Trial): Does CBT Work and for Whom Does It Work?
A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.
Mast Cell-Mediated Inhibition of Abdominal Neutrophil Inflammation by a PEGylated TLR7 Ligand.
Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
[Possibilities of using the 2010 McDonald criteria for early diagnosis of multiple sclerosis.]
[CHANGES IN THE QUALITATIVE AND QUANTITATIVE COMPOSITION OF GUT MICROBIOTA IN RATS DURING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS].
Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury.
Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.
Identification of VHY/Dusp15 as a Regulator of Oligodendrocyte Differentiation through a Systematic Genomics Approach.
Freedom from disease activity in multiple sclerosis.
Deafness in Patients with Multiple Sclerosis.
Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone.
Resequencing and fine-mapping of the chromosome 12q13-14 locus associated with multiple sclerosis refines the number of implicated genes.
How to treat tumefactive demyelinating disease?
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
The recurrent Guillain-Barré syndrome: a long-term population-based study.
CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.
Modifiable Comorbidities and Disability in Multiple Sclerosis.

Pages